This clinical trial is focused on patients with Type 2 Diabetes who have not experienced any previous cardiovascular events. The study aims to evaluate the effectiveness and safety of two medications: colchicine and non-enteric coated aspirin. These medications will be tested both individually and in combination to see if they can improve heart health outcomes in people with diabetes who are at high risk but have no apparent heart disease.
Participants in the study will receive either the active medications or a placebo. The trial will monitor the time it takes for participants to experience any major heart-related events, such as heart attacks, strokes, or the need for urgent heart procedures. The study will also track any serious side effects that may occur. The goal is to determine if adding low-dose colchicine or aspirin to standard diabetes care can reduce the risk of these heart-related issues.
The study will take place over a period of time, with regular follow-ups to assess the health of the participants. The results will help understand if these medications can provide additional protection against heart problems for people with Type 2 Diabetes who have not yet shown signs of heart disease.



Denmark
Finland
France
Greece
Italy
Portugal